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Abstract
Since the identification of the p38 mitogen-activated protein kinase
(MAPK) as a key signal-transducing molecule in the expression of
the proinflammatory cytokine tumor necrosis factor (TNF) more
than 10 years ago, huge efforts have been made to develop
inhibitors of p38 MAPK with the intent to modulate unwanted TNF
activity in diseases such as autoimmune diseases or sepsis.
However, despite some anti-inflammatory effects in animal models,
no p38 MAPK inhibitor has yet demonstrated clinical efficacy in
human autoimmune disorders. One possible reason for this
paradox might relate to the fact that the p38 MAPK signaling
cascade is involved in the functional regulation of several different
cell types that all contribute to the complex pathogenesis of human
autoimmune diseases. In particular, p38 MAPK has a multifaceted
role in CD4 T cells that have been implicated in initiating and
driving sustained inflammation in autoimmune diseases, such as
rheumatoid arthritis or systemic vasculitis. Here we review recent
advances in the understanding of the role of the p38 MAPK
signaling cascade in CD4 T cells and the consequences that its
inhibition provokes in T cell functions in vitro and in vivo. These
new data suggest that p38 MAPK inhibitors may elicit several
unwanted effects in human autoimmune diseases but may be
useful for the treatment of allergic disorders.
Introduction
The mitogen-activated protein kinase (MAPK) family
comprises at least four groups, namely p38, extracellular
signal-related kinases 1 and 2 (ERK1 and ERK2), Jun amino-
terminal kinases (JNKs), and ERK5. Within this family, the
p38 MAPK was characterized in 1994 by Han et al. as a
protein kinase that was tyrosine phosphorylated in
mammalian cells in response to lipopolysaccharide (LPS) and
extracellular changes in osmolarity, linking the p38 MAPK
signaling pathway to stress-induced responses [1]. The p38
MAPK became an interesting therapeutic target in
inflammatory diseases because in the same year Lee et al. [2]
showed that the p38 MAPK has a pivotal role in mediating
tumor necrosis factor (TNF) production by macrophages in
response to stimulation with LPS. Since then, many different
inhibitors have been developed that have greatly facilitated
the definition of the role of p38 MAPK in many biologic
systems. By using these inhibitors in combination with
transgenic mice expressing constitutively active or inactive
forms of p38 MAPK, p38 MAPK was shown to be involved in
many cellular responses in mammalian cells including cell
cycle regulation [3], cell death [4], cell development, and cell
differentiation [5]. In the immune system, the p38 MAPK
signaling cascade has been implicated in the regulation of
innate immunity, for example by mediating endotoxin-induced
TNF expression, and also in the regulation of adaptive
immunity, for example by controlling T cell activation and
differentiation [5].
Antigen-presenting cells (APCs) activate CD4 T cells by
presenting their specific antigen in the context of appropriate
major histocompatibility complex (MHC) class II molecules.
The antigen is recognized by T cells by means of their
antigen-specific T cell receptor (TCR). In addition to the
MHC–TCR contact, APCs and T cells communicate through
co-stimulatory molecules, such as CD80 and CD86
expressed by APCs and their ligand, CD28 expressed by
T cells, and through cytokines. Once activated, CD4 T cells
proliferate and differentiate into two main subsets of primary
effector cells, T helper type 1 (Th1) or Th2 cells,
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characterized by their specific cytokine expression pattern
[6]. Th1 cells promote cellular immunity and macrophage
activation largely through the production of their signature
proinflammatory cytokine IFN-γ. They control immune
responses against microbial infections and intracellular
parasites and are involved in the development of autoimmune
inflammatory diseases such as rheumatoid arthritis [7,8]. Th2
cells, through the expression of IL-4, IL-5, and IL-13, induce
IgE production by B cells and eosinophil-mediated and mast-
cell-mediated immune responses, and orchestrate the
defense against extracellular parasites [9]. Th2 cells have a
central role in driving the immune response in asthma and
atopic diseases [10]. In addition, Th2 cells, through the
production of IL-4, downmodulate Th1 differentiation and
macrophage activation and may have regulatory capacities
for Th1-mediated inflammation [11]. The Th1/Th2 balance is
therefore considered to be pivotal in chronic inflammatory
diseases, such as rheumatoid arthritis, in which excessive
Th1 inflammation may be a consequence of impaired Th2
differentiation [12]. The nature of a T cell response, namely a
Th1 or Th2 response, is modulated by the strength of the
MHC–TCR contact, the nature of the co-stimulatory signals,
and the nature of the cytokine environment during T cell
priming [13]. Integration of these different extracellular
signals within T cells is accomplished by several signaling
cascades, including the p38 MAPK pathway. Indeed,
disruption of the p38 MAPK signaling cascade can affect T
cell differentiation as well as T cell effector functions.
In addition to T cells, macrophages also have an essential
role in autoimmune disorders, for example through the
production of the proinflammatory cytokines TNF and IL-1.
Because the p38 MAPK signaling cascade has been
implicated in TNF expression, p38 MAPK is considered to be
a potential therapeutic target for inflammatory disorders such
as autoimmune diseases, and several p38 MAPK inhibitors
are currently in clinical trials. However, because T cells and
macrophages both are involved in autoimmune inflammation
and because the function of both is regulated by the p38
MAPK signaling cascade, understanding the function of p38
MAPK in human T cells may be extremely valuable with
regard to clinical applications of p38 MAPK inhibitors.
The p38 MAPK signaling cascade
Four p38 MAPK isoforms have been characterized, namely
p38α, p38β, p38γ, and p38δ, which have in common a 12-
amino-acid activation loop containing a TGY motif located at
amino acid position 180 to 182. CD4 T cells predominantly
express the p38α and p38δ isoforms [14]. Activation of p38
MAPK occurs by the phosphorylation of Thr180 and Tyr182,
leading to conformational reorganization of the enzyme and
binding of ATP and the phosphoryl acceptor (substrate). Two
different sequential binding mechanisms for ATP and the
substrate have been proposed [15,16], although the order in
which ATP and the phosphoryl acceptor bind may occur
randomly and may depend on the phosphoryl acceptor [15].
The rate-limiting step in the kinetic mechanism of p38 MAPK
activation is still unknown but may be of great importance in
designing new inhibitors of p38. More than 100 different p38
MAPK inhibitors have been reported so far, and all are
competitive with ATP. However, and in contrast to ATP, these
compounds can bind to both the active and inactive
(unphosphorylated) forms of p38, providing an advantage
over ATP and resulting in a very potent inhibitory capacity,
regardless of high intracellular ATP concentrations [17].
Since the first generation of p38 MAPK inhibitors, like the
pyridinyl imidazole compound SB203580, which have been
shown to affect several unrelated kinases, the understanding
of the kinome has greatly improved and has facilitated the
development of more selective inhibitors [18]. These new
molecules have now helped to clarify the role of p38 MAPK in
vitro and to define the mechanisms by which p38 MAPK
controls for example LPS-induced cytokine expression in
macrophages [19].
Activation of p38 MAPK
The MAPK pathway is similar for all the members of the
MAPK family and is typically composed of a highly conserved
MAPK module comprising three kinases, namely MAPK
kinase kinase (MKKK), MAPK kinase (MKK), and MAPK [20]
(Fig. 1). In the p38 MAPK cascade, MEKK4 (an MKKK)
activates MKK3, MKK4, or MKK6, which subsequently
phosphorylate p38 MAPK at Thr180 and Tyr182 [21,22]
(Fig. 1). The mechanisms regulating the activation of the
MAPK module are very complex, in particular in T cells in
which the TCR and CD28 act synergistically to induce
intracellular cell signaling.
One critical event after stimulation of the TCR that is
essential for activation of the MAPK signal cascade is the
recruitment of linker for activation of T cells (LAT) and the
activation of guanine nucleotide exchange factors (GEFs).
GEFs activate small GTP-binding proteins such as Ras, Rac-
1, and Cdc42 by promoting the conversion of the GDP-
bound inactive state to the GTP-bound active state, leading
to the activation of the MAPK signaling cascade. Activation of
the p38 MAPK cascade in Jurkat T cells has been shown to
require phosphorylation of the GEF Vav by Zap-70 and
subsequent activation of Rac-1. CD28 co-stimulation
augments the recruitment of Vav to LAT and Zap-70 and
increases Zap-70 mediated Vav phosphorylation [23]. Rac-1
elicits the p38 MAPK cascade through the p21-activated
kinase 1 (Pak1), although the exact mechanism remains
unclear because Pak1 does not directly activate an MKKK
[24].
Direct upstream activators of MKKKs are the growth arrest
and DNA damage-inducible genes 45 (GADD45) proteins,
which are important in the regulation of p38 MAPK activity in
T cells [25,26]. GADD45 proteins can bind the autoinhibitory
domain of MEKK4 (MKKK), which is an upstream activator of
p38 MAPK and JNK, and relieve the autoinhibition of MEKK4,Page 3 of 11
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leading to activation of the MAPK cascade [27]. Whether
GADD45 proteins are activated by Pak1 remains to be
elucidated. Interestingly, the activation of p38 MAPK by
cytokines seems to occur in two phases that can be
regulated by two different mechanisms: a rapid but brief
GADD45β-independent activation followed by a delayed but
sustained GADD45β-dependent activation [28,29]. Although
data on the role and mode of activation of GADD45 proteins
in T cells are still controversial, the regulation of the
expression levels of GADD45 proteins constitutes an indirect
additional mechanism to control the intensity and duration of
p38 MAPK activation.
An alternative pathway for p38 MAPK activation in T cells has
been recently described in which dual phosphorylation of
Thr180 and Tyr182 is not induced by an MKK but by p38
MAPK itself. Stimulation of the TCR induces phosphorylation
of p38 MAPK on Tyr323 through Zap70, which subsequently
leads to autophosphorylation of Thr180 and Tyr182 [30]. It
has been suggested that in T cells, the classical pathway in
which GADD45 proteins activate MEKK4 might be induced
predominantly by stress signals, whereas the alternative
pathway might be activated by TCR stimulation [31]. How-
ever, p38 MAPK phosphorylation induced by TCR ligation is
impaired in GADD45β-deficient naive T cells [28], indicating
that both the classical pathway and the alternative pathway
are required for p38 MAPK activation in T cells (Fig. 1).
Inactivation of p38 MAPK
The level of protein phosphorylation is controlled by the
coordinated activities of kinases and phosphatases.
Dephosphorylation of either Thr180 and Tyr182 is sufficient
to inactivate p38 MAPK and can be mediated by tyrosine-
specific MAPK phosphatases (TS-MKPs) such as phospho-
tyrosine phosphatase SL (PTP-SL), serine/threonine-specific
MKPs (SS-MKPs) such as protein phosphatase type 2A
(PP2A), or tyrosine and threonine dual-specificity phosphatases
(DS-MKPs) such as MKP1. The MAPK cascade can induce
phosphatase gene transcription, providing a negative
feedback for MAPK activation [32]. Another mechanism of
inactivation of p38 MAPK is mediated by GADD45α, which
has recently been shown to inhibit the activation of p38
MAPK by the alternative pathway, but not by the classical
pathway, in T cells but not in B cells [33] (Fig. 1). Similarly,
GADD45β can inhibit the JNK pathway by binding one of its
upstream activators, MKK7 [34]. These observations are
intriguing because GADD45 proteins are, as mentioned
above, also activators of the MAPK signaling cascade and
therefore seem to be important in regulating p38 MAPK
activity by exerting both activating and inactivating effects.
Substrates of p38 MAPK
All the MAPKs phosphorylate a threonine or a tyrosine, which
is immediately followed by a proline residue. This ‘P + 1’
sequence is the most reliable consensus motif for MAPK
substrates [35]. The specificity of the different members of
the MAPK family and of the different isoforms of p38 MAPK is
provided by a docking motif usually composed of three
domains: the basic region, the LXL motif, and the hydro-
phobic region. The hydrophobic region seems to be of
particular importance for the determination of the substrate
specificity for p38 MAPK [36]. The development of models to
predict p38 MAPK docking-domain specificities may permit
the design of inhibitory peptides to block the phosphorylation
of specific subsets of substrates so as to block specific
pathways mediated by p38 MAPK [37].
p38 MAPK substrates can be divided into two categories,
namely transcription factors and protein kinases (Table 1).
Several of the protein kinases activated by p38 MAPK are
involved in the control of gene expression at different levels.
Mitogen- and stress-activated kinase 1 and 2 (MSK1/2), for
example, can directly activate transcription factors such as
cAMP-response element-binding protein (CREB), activating
transcription factor 1 (ATF1), NF-κB p65, signal transducers
and activators of transcription (STAT1), and STAT3 [38-41],
but can also phosphorylate the nucleosomal proteins histone
H3 and high-mobility-group 14 (HMG-14). Either by inducing
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Figure 1
The p38 mitogen-activated protein kinase (MAPK) signaling cascade in
T cells. Activation of p38 MAPK requires dual phosphorylation at
Thr180 (T180) and Tyr182 (Y182) and can be mediated by two
different pathways in T cells. The classical pathway is formed by a
conserved MAPK module and is activated by the T cell receptor (TCR),
CD28, or the IL-12/IL-18 receptors through growth arrest and DNA
damage-inducible genes (GADD)45α or GADD45β. The alternative
pathway is activated by the TCR and induces the phosphorylation of
p38 MAPK at Tyr323 (Y323) and subsequent autophosphorylation of
p38 MAPK at Thr180 and Tyr182 that can be blocked by GADD45α.
MKK, MAPK kinase; ζ2, zeta chain homodimer.chromatin remodeling or by recruiting the transcriptional
machinery, these two proteins are important for the rapid
induction of immediate-early genes that occurs in response to
stress or mitogenic stimuli [42]. In contrast to MSK1/2, which
preferentially activates transcription, MAP kinase-activated
protein kinase 2 (MK2) participates in the control of gene
expression at the post-transcriptional level by phosphorylating
tristetraprolin (TTP) or heat shock protein 27 (hsp27) [43].
Stimuli activating p38 MAPK
Environmental stress such as osmotic shock activates p38
MAPK in almost every mammalian cell. A variety of other
stimuli, such as cell–cell contact or soluble factors such as
cytokines, are also able to activate p38. In T cells, the p38
MAPK is activated by contact with APCs or by different
cytokines. Triggering of the TCR alone leads to activation of
the p38 MAPK pathway in naive and memory CD4 T cells.
However, several reports have demonstrated that full
activation of p38 MAPK in vitro requires co-stimulation in
addition to TCR stimulation. The co-stimulatory molecules
CD28, 4-1BB, CD26, CD30, inducible co-stimulator (ICOS),
and erythropoietin-producing hepatocyte B6 (EphB6) have
been shown to activate p38 MAPK synergistically with TCR
stimulation [44-50]. Interestingly, ligation of CD30, CD28, or
EphB6 also activates p38 MAPK in the absence of TCR
ligation [46,47,49,51]. However, the requirement for p38
MAPK activation with regard to co-stimulatory receptor
ligation differs between T cell subsets. Whereas the p38
MAPK pathway can be activated by CD28 stimulation alone
in memory CD4 T cells, naive T cells strictly require
concomitant TCR signaling [51], indicating that naive T cells
are lacking an important molecule necessary to link the CD28
signaling to the p38 MAPK signaling cascade. This
deficiency might contribute to the higher activation threshold
of naive T cells than that of memory T cells.
In addition to co-stimulatory molecules, some cytokine
receptors can activate p38 MAPK in T cells. The IL-12
receptor, for example, has been shown to signal by means of
the p38 MAPK cascade in activated T cells. However,
activation of p38 MAPK by IL-12 alone is only transient (less
than 20 minutes) [52]. Sustained activation of p38 MAPK can
be observed by simultaneous stimulation with IL-12 and IL-18
and requires the expression of GADD45β [28]. Whether
IL-12/IL-18 directly activates GADD45β or simply induces its
expression remains a matter of debate [26,28]. IL-4 and IL-2
have been shown to induce p38 MAPK activation in the
murine T cell line CT6 but not in primary T cells [51,53,54]. In
our hands, IL-4 was unable to activate p38 MAPK in primary
naive and memory human CD4 T cells (F Dodeller, A
Skapenko, H Schulze-Koops, unpublished data). This could
be related to the relatively low expression of the IL-4 receptor
in primary cells in comparison with the murine cell line, but
also to differences in the signaling pathway of IL-4 in primary
human T cells and T cell lines [53]. Interestingly, p38 MAPK
has been implicated in IL-4 receptor signaling in human
airway smooth muscle cells [55] and in murine B cells [56].
Regulation of cytokine expression by p38
MAPK in CD4 T cells
Expression of IFN-γ γ, TNF, and IL-2
Because of the critical role of IFN-γ in inflammation, the
delineation of the molecular mechanisms controlling the
expression of IFN-γ has been the focus of many studies. IFN-γ
expression can be induced in CD4 T cells either by antigen-
specific stimulation or by co-stimulation with IL-12 and IL-18.
Although both stimuli activate p38 MAPK and IFN-γ
production, it remains controversial whether antigen
stimulation signals through p38 MAPK to induce IFN-γ
expression. Two different reports have demonstrated that
inhibition of p38 MAPK in Th1 cells differentiated in vitro
decreased IFN-γ expression induced by IL-12/IL-18
stimulation, but not that induced by antigen stimulation
[57,58]. In contrast, inhibition of p38 MAPK in splenic T cells
decreased IFN-γ expression induced by CD3 and
CD3/CD28 stimulation [44]. Similarly, Flavell et al. have
shown that the expression of a dominant-negative mutant of
p38 MAPK or a constitutive active mutant of p38 MAPK in
murine Th1 effector cells resulted in decreased or increased
IFN-γ expression, respectively [59]. However, because those
Th1 cells were differentiated in vitro by the addition of IL-12
before antigen re-stimulation, it is not completely resolved
Arthritis Research & Therapy    Vol 8 No 2 Dodeller and Schulze-Koops
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Table 1
Typical substrates of p38 mitogen-activated protein (MAP)
kinase
Substrate Reference
Transcription factors
Activating transcription factor 2 (ATF2) [119]
SRF accessory protein 1 (Sap1) [120]
C/EBP homologous protein (CHOP) [121]
p53 [122]
Myocyte enhancer factor 2A (MEF2A) [123]
Myocyte enhancer factor 2C (MEF2C) [124]
CAAT-enhancer binding protein β (C/EBPβ) [125]
Nuclear factor of activated T cells p (NFATp) [74]
Signal transducers and activators of transcription  [79]
(STAT4)
Protein kinases
MAP kinase-activated protein kinase 2  [126]
(MAPKAPK2 or MK2)
MAP kinase-activated protein kinase 3 (MK3) [127]
MAP kinase interaction protein kinase 1 (MNK1) [128]
p38 regulated/activated kinase (PRAK) [129]
Mitogen- and stress-activated kinase 1 and 2 (MSK1/2) [130]whether the inactive or active mutants of p38 MAPK affected
only Th1 differentiation induced by IL-12 or modulated IFN-γ
expression induced by antigen stimulation.
Similarly to the situation in the mouse, in human T cells p38
MAPK seems to preferentially modulate IFN-γ expression that
is induced by IL-12 rather than that induced by TCR
stimulation (Fig. 2) [60]. We have recently shown that
although p38 MAPK does not control IFN-γ expression
induced by TCR and CD28 stimulation in human T cells, a
moderate and transient reduction of IFN-γ expression
occurred after inhibition of p38 MAPK in the presence of
IL-12, indicating that the p38 MAPK pathway is involved in
mediating IL-12-induced IFN-γ expression [60]. Interestingly,
whereas IFN-γ expression induced by TCR/CD28 stimulation
seems to be independent of p38, that induced by stimulation
by means of the TCR and the co-stimulatory receptor CD26
(A6H antigen) was decreased in the presence of a p38
MAPK inhibitor [47], suggesting that different co-stimulatory
molecules might induce IFN-γ expression through the p38
MAPK pathway.
In marked contrast to myeloid cells, in which the p38 MAPK
pathway is the main pathway involved in the expression of the
proinflammatory cytokine TNF, p38 MAPK activation is not
required for TNF expression in T cells [60,61], emphasizing
that the function of p38 MAPK is cell type specific. Inhibition
of the p38 MAPK signaling cascade downregulates IL-2
promoter activity and IL-2 production in Jurkat T cells [62]. In
primary T cells, however, although inhibition of p38 MAPK
modulated IL-2 promoter activity [62], it did not reduce but
could in some cases even increase the expression of IL-2
[60,63-65]. Interestingly, the inhibitory effect of p38 MAPK
on IL-2 expression could be shown to be a consequence of
the inhibition of ERK activity [63].
Expression of IL-4, IL-5, and IL-13
The role of p38 MAPK in IL-4, IL-5, and IL-13 expression
depends on the nature of both the stimulus and the cells
involved. Whereas the expression of IL-4 and IL-5 induced by
stimulation of in vitro-differentiated murine Th2 cells with
concanavalin A remained unaffected by the chemical inhibitor
of p38 SB203580 or a dominant-negative mutant of p38, the
induction of IL-4 by phorbol 12-myristate 13-acetate and
ionomycin or of IL-5 and IL-13 by phorbol 12-myristate 13-
acetate and dibutyryl cAMP was partly abrogated by
SB203580 [59,66]. In murine splenic T cells, CD3-induced
and CD3/CD28-induced IL-4 expression as well as CD30-
induced IL-13 expression were also partly abrogated by
SB203580 [44,46,67]. In human CD4 T cells, inhibition of
p38 MAPK by SB203580 or by a dominant-negative mutant
of p38 MAPK reduced the expression of IL-4, IL-5, and IL-13
in response to CD3 and/or CD28 stimulation [60,61],
indicating that the p38 MAPK pathway has a critical role in
the regulation of Th2 cytokine expression in primary human T
cells (Fig. 2). In contrast, the production of IL-4, IL-5, and IL-
13 by in vitro-activated established human Th2 effector cells
was only moderately affected by p38 MAPK inhibition,
suggesting that additional pathways mediate the expression
of these cytokines in effector Th2 cells in comparison with
primary T cells [60]. In line with this observation, the inhibition
of p38 MAPK in Th2 cell clones derived from atopic
asthmatic patients partly inhibited the expression of IL-5 but
did not alter that of IL-4 [68]. Together, these data clearly
indicate that the role of p38 MAPK in Th2 cytokine
expression is different in primary T cells and established
effector cells and is therefore dependent on the stage of T
cell maturation.
IL-10
Early studies indicated that p38 MAPK regulates IL-10
expression in monocytes [69]. In murine and human T cells,
inhibition of p38 MAPK by SB203580 or a dominant-
negative mutant of p38 MAPK strongly diminished IL-10
expression [60,63,64,67]. In human CD4 T cells as well as in
anergic murine T cells, inhibition of p38 MAPK resulted in
diminished production of IL-10 [60,63,64]. Because IL-2 and
IL-10 are proinflammatory and anti-inflammatory cytokines,
respectively, it has been postulated that p38 MAPK might
therefore have a pivotal role in the maintenance of T cell
unresponsiveness in anergic T cells [63].
Regulation of cytokine gene transcription
The nuclear factor of activated T cells (NFAT) family of
transcription factors has a critical role in T cell effector
functions, and NFAT DNA-binding sites have been identified
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Figure 2
The role of p38 mitogen-activated protein kinase (MAPK) in human T
cell effector functions. The activation of p38 MAPK in T cells
downstream of the T cell receptor and CD28 is necessary for the
expression of IL-10 and of the T helper type 2 (Th2) cytokines IL-4,
IL-5, and IL-10, but not for that of the Th1 cytokine IFN-γ. In Th1 cells,
however, p38 MAPK is involved in the expression of IL-12-induced
IFN-γ production.in many different cytokine genes, for example those of IL-2,
IL-4, and IFN-γ [70-72]. p38 MAPK can positively and
negatively modulate NFAT activity by several mechanisms.
p38 MAPK can induce NFAT expression at the transcriptional
and post-transcriptional levels and can promote the inter-
action of NFAT with the coactivator CREB-binding protein
(CBP). In contrast, p38 MAPK can inhibit NFAT transcrip-
tional activity by phosphorylation of NFAT and by activation of
NFAT nuclear export [73,74].
An alternative transcription factor that is regulated by p38
MAPK is the Th2-specific transcription factor GATA-3 [66].
Intensive investigations have demonstrated the fundamental
function of GATA-3 in Th2 immune regulation and have
shown that GATA-3 can directly activate the IL-5 and IL-13
promoters and induce chromatin remodeling at the il4 locus.
However, the molecular mechanisms that regulate GATA-3
activity are unclear. One report has claimed that
phosphorylation of GATA-3 occurs in Th2 cells and that this
phosphorylation was mediated by p38 MAPK [66].
The transcription factor C/EBPβ is a direct substrate of p38.
Interestingly, C/EBPβ can bind to the IL-4 promoter, and
retroviral overexpression of C/EBPβ in thymoma cells
induced IL-4 gene expression and decreased IFN-γ and IL-2
mRNA levels [75].
STAT transcription factors mediate the induction of gene
expression downstream of cytokine receptors and therefore
have an essential role in the immune response. After ligand
binding, STAT proteins are recruited to the cytokine
receptors and phosphorylated on tyrosine residues by Janus
tyrosine kinases (Jaks) [76]. Interestingly, in addition to
tyrosine phosphorylation, STAT proteins in vertebrates can
also be phosphorylated at a serine residue [77]. Stimulation
by IL-12, for example, induces STAT4 phosphorylation at
both tyrosine and serine residues. Serine phosphorylation is
required for full activation of STAT4-induced transcription and
IFN-γ expression and it has been shown that this essential
phosphorylation step is mediated by p38 MAPK [78,79]. The
p38 MAPK signaling pathway has also been implicated in IL-
12-induced IFN-γ expression in a STAT4-independent
pathway [80], probably by means of the transcription factor
ATF2 [52].
In macrophages, the induction of IL-10 expression by LPS
requires activation of the p38 MAPK pathway. In these cells,
the inhibition of p38 MAPK affects the activity of the IL-10
promoter by inhibiting binding of the transcription factor Sp1
[81]. Whether p38 MAPK controls IL-10 expression through
Sp1 in T cells remains to be shown.
The transcription factor CREB can be activated by the
calcium/calmodulin-dependent protein kinase IV (CaMKIV)
[82] and by the p38 MAPK pathway by means of MK2 or
MSK1/2 [40,83]. Studies of the role of CREB in T cells have
provided conflicting results with regard to whether CREB is a
positive or negative regulator of cytokine transcription.
Reduction of CREB expression by using short interfering
RNA or neutralization of CREB with an intracellular antibody
in T cells decreased IFN-γ expression induced by activated
macrophages [84]. Similarly, CD4 T cells expressing a
dominant-negative mutant of CREB showed defective
expression of IL-2, IL-4, and IFN-γ. However, this defect was
secondary to the inability of these cells to express the
inhibitor of programmed cell death, Bcl-2, leading to impaired
T cell differentiation [85]. In CaMKIV-deficient mice, whereas
naive T cells did not express any apparent defect in cytokine
expression, the expression of IL-2, IL-4, and IFN-γ was
decreased in a subpopulation of CD4 T cells with a memory
phenotype. This defect reflected the incapacity of these cells
to activate CREB and the expression of the CREB-
dependent immediate-early genes c-jun, fosB, fra2, and junB
that are necessary for cytokine gene expression [86]. In
contrast, overexpression of CREB in Jurkat T cells has been
shown to downmodulate IFN-γ promoter activity directly [87].
These data suggest that CREB may have a dual role in
cytokine expression in CD4 T cells by directly blocking the
IFN-γ promoter and by indirectly regulating T cell
differentiation or cytokine gene transcription factors.
However, the role of p38 MAPK with regard to CREB
function in T cells remains to be elucidated.
Another mechanism by which p38 MAPK may modulate
cytokine gene transcription in T cells may be through the
regulation of gene accessibility. Indeed, histone phosphory-
lation, as well as acetylation or methylation, locally affects the
chromatin structure and subsequently gene expression. The
p38 MAPK cascade can induce the phosphorylation of, for
example, the histone H3 by means of MSK1 [88]. In dendritic
cells, phosphorylation of histone H3 by the p38 MAPK
signalling pathway was necessary for the expression of IL-8
and MCP-1 in response to stimulation with LPS. Phosphory-
lation of H3 enhanced the accessibility of these genes,
leading to recruitment of NF-κB and induction of gene
transcription [89]. Whether a similar mechanism occurs in T
cells is currently unknown.
Regulation of cytokine mRNA stability
Regulation of mRNA turnover is an important mechanism in
the control of gene expression. mRNA stability is mediated by
AU-rich sequences present in the 3′ untranslated region.
These AU-rich elements (AREs) are involved in mRNA
stabilization or destabilization by means of specific RNA-
binding proteins. AREs are present on many cytokine mRNAs
and are required for p38-mediated mRNA stability [90]. The
p38 MAPK pathway has been shown to affect the mRNA
stability of proinflammatory genes, mainly that of mRNA for
cytokines such as IL-2, IL-3, IL-6, IL-8, TNF, and GM-CSF
[90-92] but also that of mRNA for cyclo-oxygenase 2 (COX-
2) [93], vascular endothelial growth factor (VEGF) [94],
macrophage inflammatory protein 2 (MIP-2) [91], urokinase-
Arthritis Research & Therapy    Vol 8 No 2 Dodeller and Schulze-Koops
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MK2 is one of the members of the p38 MAPK pathway
implied in mRNA stabilization. One mechanism by which MK2
may regulate mRNA stability is through the phosphorylation
and inactivation of the zinc finger protein TTP. Binding of TTP
to AREs in the 3′ untranslated region leads to the rapid
degradation of target mRNA. Phosphorylation of TTP by MK2
has been shown to induce the binding of 14-3-3 proteins to
TTP, thereby withholding TTP from the mRNA degradation
machinery [97,98]. However, it should be noted that the
interaction of 14-3-3 proteins with TTP and its role in mRNA
stabilization has been recently questioned [99]. An additional
mechanism by which MK2 may regulate mRNA stability may
be through the phosphorylation of the heterogeneous nuclear
ribonucleoprotein A0 (hnRNP A0), which then binds to the
AREs of TNF, COX-2, and MIP-2 mRNA and stabilizes these
mRNAs [91]. In T cells, stabilization of cytokine mRNA occurs
after the stimulation of the TCR and CD28 [100]. The
importance of mRNA stability for the effector functions of T
cells has been demonstrated in two different mouse strains in
which the Th1 and Th2 bias and the susceptibility to
hypersensitivity pneumonitis were correlated with the stability
of IL-4 and IL-13 mRNA [101]. We have recently shown that
in human memory CD4 T cells, stabilization of IL-4 and IL-13
mRNA by CD28 stimulation is mediated by p38 MAPK [60].
Thus, p38 MAPK is involved in regulating T cell cytokine
expression in part by modulating mRNA stability, the precise
molecular mechanism of which remains to be characterized.
Therapeutic inhibition of p38 MAPK for T cell-
mediated inflammatory diseases
Th1 cells, through the production of IFN-γ, are potent
activators of TNF production by macrophages. The pivotal
role of TNF in autoimmune diseases is underlined by the
success of therapies antagonizing TNF either with mono-
clonal antibodies or soluble TNF receptors. Characterizing
the signaling pathways that control TNF and IFN-γ expression
may therefore be of major interest for the development of low-
molecular-mass compounds capable of blocking TNF
production that may be orally bioavailable and cheaper to
produce than the currently available biologicals [102].
Because of its essential role in TNF and IFN-γ expression by
macrophages and T cells, respectively, the p38 MAPK
signaling cascade is considered a promising therapeutic
target for Th1-mediated inflammatory diseases [103]. Several
synthetic p38 MAPK inhibitors have demonstrated protective
anti-inflammatory effects in animal models of arthritis, such as
collagen-induced arthritis in mice or adjuvant-induced arthritis
in Lewis rats [104-110]. However, none of these molecules
has yet successfully passed early clinical trials for the treat-
ment of human autoimmune diseases because of safety
concerns related to possible cross-reactivities with other
kinases. Two different p38 MAPK inhibitors, BIRB-796 and
RWJ-67657, have demonstrated clinical efficacy in a human
endotoxin challenge model in which the inhibition of p38
MAPK was shown to decrease LPS-induced cytokine and C-
reactive protein (CRP) production in vivo and to reduce LPS-
induced clinical symptoms, for example those of sepsis (such
as increased heart rate, decreased blood pressure, fever, and
headache) [111,112]. Recently, a different p38 MAPK
inhibitor, VX-702, was shown to reduce serum C-reactive
protein levels in patients with acute coronary syndrome [113].
These data suggest that in humans, p38 MAPK activation is
essential in acute inflammatory processes such as sepsis or
acute coronary syndrome, but its precise function in chronic
inflammatory processes such as those mediating autoimmune
diseases remains unclear. In particular, it remains to be
defined which stimulus induces TNF expression in
autoimmune inflammation and whether p38 MAPK controls
TNF production induced by this stimulus.
In contrast to Th1-mediated autoimmune disorders, allergic
disorders are mediated by Th2 cells through the production
of IL-4, IL-5, and IL-13. Because of its central role in Th2
effector functions (Fig. 2), it is reasonable to assume that p38
MAPK may also be important in allergic inflammation. In this
regard, it has been shown that in the ovalbumin-induced
airway inflammation model, eosinophilia was decreased by
inhibition of p38 MAPK in mice and guinea-pigs [114,115].
Inhibition of p38 MAPK expression with antisense oligo-
nucleotides in ovalbumin-challenged mice reduced eosino-
philia, pulmonary cell infiltration, mucus production, airway
hyperreactivity, and Th2 cytokine levels in bronchoalveolar
fluids [116]. Similarly, in ovalbumin-sensitized rats, allergic
airway inflammation could be reduced if p38 MAPK was
inhibited before allergen challenge [117]. Interestingly,
however, inhibition of p38 MAPK did not affect the resolution
of the pulmonary edema in previously established inflam-
mation in rats [117]. It is tempting to speculate that this
process is independent of T cells. These observations
indicate that p38 MAPK is essential for the development of
allergic inflammation, probably by controlling Th2 effector
functions, and suggest that the p38 MAPK signaling cascade
might be an interesting therapeutic target for allergic
diseases.
Inhibitors of the third generation that are currently in clinical
trials will, it is hoped, permit a better characterization of the
role of p38 MAPK in humans. However, their use in the clinic
warrants further studies to establish and eventually improve
their selectivity over the human kinome [18]. Targeting down-
stream molecules of p38 MAPK or the development of non-
ATP-competitive inhibitors of p38 MAPK may be attractive
alternative approaches to the therapeutic disruption of p38
MAPK-mediated effects [118].
Conclusion and perspectives
The characterization of p38 MAPK as a key player in
inflammation more than 10 years ago led to the development
of several p38 MAPK inhibitors for the treatment of inflam-
matory autoimmune diseases. Although these inhibitors were
potent in animal models of autoimmune diseases and in
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with p38 MAPK inhibitors have been discontinued because
of serious side effects, in particular at the level of the central
nervous system. New p38 MAPK inhibitors that are unable to
cross the blood–brain barrier are now in clinical trials in
rheumatoid arthritis and will delineate precisely the role of
p38 MAPK in Th1-driven chronic inflammatory diseases.
However, in view of recent advances underlining the essential
role of p38 MAPK in IL-10 expression and in Th2 cell
functions and of the regulatory capacities of IL-10 and Th2
cells in Th1-driven inflammation, p38 MAPK inhibitors might
be associated with some unwanted effects on the immune
system, enhancing rather than ameliorating the underlying
inflammatory response in Th1-driven diseases. In contrast,
these inhibitors may be useful as therapy in Th2-driven
inflammatory disorders. However, as p38 MAPK also has
essential functions in other organ systems beside the immune
system, it may be necessary to characterize precisely the
signal cascades downstream of p38 MAPK that control
effector functions in the immune system to identify those that
are involved in unwanted immune responses without
interfering with essential physiologic functions of the p38
MAPK signaling cascade in other organ systems. This might
provide therapeutic targets to specifically block, for example,
TNF production by macrophages in autoimmune diseases or
Th2 effector functions in allergic disorders.
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